Major discoveries have been made in the past few years on the structure and mode of biosynthesis of serum albumin. The complete amino acid sequence of this protein has been determined, and its covalent structure shown to be a single peptide chain grouped into a series of nine disulfide-bonded loops. These loops appear to associate into three similar domains. By study of isolated fragments of the molecule it can be demonstrated that the binding of bilirubin and the primary binding of long-chain fatty acids are functions of separate domains. The biosynthesis of albumin has been found to involve a precursor form, termed "proaibumin," in which a basic hexapeptide is attached to the amino end of the chain. Similar precursor forms are now known to have a role in the formation of other secreted proteins, but in the case of albumin the purpose of the additional peptide is not clear.
Introduction
Serum albumin is the most abundant and the most studied of the proteins of the circulation. One of the first proteins to be recognized, its name derives from the early name for proteins, albumen, derived from the Latin word albus, white-in this case, white of an egg. Albumins in serum were initially defined as those proteins soluble in water in the absence of salts, in contrast to globulins, which are insoluble under such conditions. Albumin was being measured in the clinical laboratory before 1921, when the use of sodium sulfate for fractionation (1) was introduced. Yet the primary function of this major protein remains uncertain, and the methods in use for its assay are unsatisfactory.
Known functions attributed to albumin include the binding and transport of long-chain fatty acid anions, the binding and detoxification of unconjugated bilirubin, and a secondary or backup role in transport of thyroid and steroid hormones (2) . The biosynthesis of albumin is closely dependent on the amino acid supply, so closely that the rate of albumin synthesis probably increases after each meal. Hence albumin has a minor nutritive role, acting as a reservoir and contributing about 5% of the amino acids used by peripheral tissues. Through its osmotic effect, albumin is the major contributor to the maintenance of the circulating fluid within the vascular system. Indeed, over 7 million units, 10 000 kg of albumin, are dripped annually into the veins of patients who have various degrees of circulatory collapse or metabolic depletion (3) ; the efficacy of this treatment is still under debate. Measurement of albumin is considered to have diagnostic value as an indication of vascular integrity, of the nutritional status regarding proteins, and, to some extent, of the functional reserve of the liver.
The availability of bovine albumin in high purity at reasonable cost, a by-product of the intensive efforts of E. J. Cohn and his collaborators at the Harvard Physical Chemistry Laboratory under American Red Cross auspices during World War II, has made this particular protein a favorite for study by protein chemists. Despite intensive investigation, detailed knowledge of the structure of albumin has been slow in appearing, and only in recent years has there been exciting progress in elucidating its amino acid sequence, its covalent structure, and unpredicted aspects of the mode of its biosynthesis.
This communication will review these developments in structure and biosynthesis, together with features of evolutionary origin and of assays available for clinical use. Attempts have been made to trace the evolutionary origin of albumin and thereby to learn its primary function. As one descends the evolutionary tree, the total concentration of circulating proteins declines, roughly in step with the decline in blood pressure. A protein similar to mammalian albumin in size, charge, and amino acid composition has been identified in low concentration in the blood streams of amphibian larvae (tadpoles) (4), and a protein closely resembling albumin circulates in bony fishes. Whether albumin is present in cartilaginous fishes (sharks, skates, and rays) is not clear (5). Albumin is found in aquatic forms, and so it apparently did not evolve as an adaptation to terrestial life. Its origins must lie in some invertebrate species, perhaps, as shall be discussed later, as a smaller protein not found in plasma of vertebrates.
Study of the evolution of albumin has yielded helpful information in the hands of A. C. Wilson and his collaborators, at Berkeley. Using careful immunochemical comparisons, Wilson showed that albumin has continued to evolve, through "neutral" (i.e., nonfunctional) amino acid changes, even in ancient species whose outward form has not changed in millions of years. Thus, greater differences are seen among albumins of different species of tree frogs than among the albumins of mammals of different orders, such as the whale and the giraffe (6). Similar studies on a more recent time frame have served to define the geological points of diversification among the primates. In terms of albumin, man is found to be more closely related to the chimpanzee and gorilla than these species are to other primates such as the orangutan (7).
Sequence and Covalent Structure
The complete amino acid sequence of human and bovine albumins was published in 1975 by J. R. Brown and his coworkers, of Austin, Texas (8, 9) . Shortly thereafter B. Meloun et al., of Prague, independently published the sequence of human albumin (10). These were monumental works, considering that albumin is a single peptide chain of over 580 residues, and that as recently as 1970 less than 10% of its sequence was known (11). Albumin appears to be the longest peptide chain for which the sequence has yet been determined.
Brown et al. also proposed a covalent structure for the albumin molecule, shown in Figure 1 . The peptide chain is pictured as a series of double loops formed by disulfide bonds between its 34 half-cystine residues. Brown deduced this structure from the occurrence of eight adjacent Cys-Cys pairs, with additional haif-Cys residues spaced at fairly regular intervals from the pairs. As a model Brown had available a fragment (12), residues 504-581, which had been isolated by peptic cleavage without disruption of disulfide bonds and shown to originate from the carboxy-terminal portion of the molecule. This fragment contained one Cys-Cys pair and two other half-Cys residues. Because adjacent Cys-Cys groups cannot form S-S bonds with each other, only the configuration shown as loop 9 in Figure 1 was possible. This led to the suggestion that the molecule consists of a series of similar double loops connected by single strands of peptide chains.
The loop-and-link construction ( Figure 1 ) can account for the well-known flexibility and stability of albumin. Reversible expansion of the molecule, which occurs when the pH is below 4, is probably explained by electrostatic repulsion of the loops from each other as they become more positively charged. The disulfide bridges would prevent a major loss in secondary structure in this situation, as well as in more severe conditions which albumin can survive, such as 8 mol/liter urea orapHofi.
In its repeating-loop structure albumin bears a resemblance to the second most prominent extracellular protein, immunoglobulin G (IgG). IgG contains four peptide chains rather than one, but each of these is made up of disulfide-bonded loops ( Figure 2 ). The longer double loops in albumin contain about 55 resi- A repeating triplet pattern can be discerned in the loop arrangements in Figure 1 , the middle loop of each triad being shorter than its neighbors. This pattern suggests that the molecule is arranged naturally into three "domains,"
containing loops 1-3, 4-6, and 7-9. There is some homology in the amino acid sequences of the three domains, implying that albumin evolved from a molecule one-third of its present size. Brown (14) proposed that the primordial "albumin" was a single double-loop, similar to loop 9, which evolved to a triplet domain by a process of gene duplication, half -duplication, and deletion of about 40 residues from the middle loop. Again there is an analogy to the immunoglobulins, which purportedly arose from a primordial molecule half the size of the L (or "light") chain, and containing one disulfide loop.
Brown also called attention to features in which albumin resembles myoglobin, particularly in the sequence Arg-His-Pro, which is found at the tips of albumin loops 3 and 6 and in a similar location at the tip of helix G of myoglobin (14) . Of more immediate clinical interest is the report of Ruoslahti and Terry (15) that a 59-residue segment of human a-fetoprotein bears a striking homology to loops 4 and 5 of human albumin; more than half of the sequenced residues are identical. This a1-globulin, which is produced during fetal life before albumin production begins, and by adult liver that has become neoplastic, may have a closer genetic relationship to albumin than has been realized.
Isolated Fragments of Albumin
A feature inherent in the loop structure of albumin and immunoglobulins is that the parts of the molecule can retain their native configuration and can perform binding functions when separated from the remainder of the molecule. The functions of different domains are The specimens were fragmentscontainingloops of the molecule as follows: (2) 1-6; (3)1-5; (4) 5-9; (5) 4-5; (6)1-3; (7)9. Gel 1contaIned bovine albumin, mol wt 66 210; gel 9 contaIned bovine albumin and cytochrome c. mol wt 12300, as markers.Directionof mipratlon is indicated by the arrow. Reproduced, by permission, from Feldhoff and Peters, Biochemistry 14, 4508 (1975) .
Copyright by the American Chemical Society apparently different. Thus, cleavage of IgG just above the "hinge" region at the branching of the "Y" by papain yields the two arms as "Fab" fragments and the stem of the Y as the "Fc" piece. The Fab fragments are stable and can bind antigens; the Fc fragment is also stable and retains its ability to fix complement. As seen below, the domains of the albumin molecule can also function autonomously.
Preparation of fragments.
Several laboratories have isolated pieces of albumin after limited proteolysis. Mild treatment with pepsin at a pH greater than 3 primarily cleaves peptide bonds in the links between loops. From such digests of bovine albumin have been isolated fragments consisting of loops 1,6, 8,9, 2-3,4-5, 1-5, 1-6, and 6-9 (16, 17) . Treatment with trypsin (1/1000, by wt) yielded fragments consisting of loops 3,7-9, and 4-9 (18, 19) . Fragments of human albumin containing loops 3, 6,4-6, 1-5, and 4-9 have been purified after treatment with pepsin or trypsin (20) . Bellon and Lapresle (21) have isolated another fragment after prolonged digestion with rabbit spleen extract. This fragment consists of parts of loop 9 and retains strong antibody-binding ability.
Electrophoretic patterns of the seven largest fragments of bovine albumin obtained after peptic cleavage of bovine albumin are shown in Figure 3 . The fragments were purified by conventional fractionation techniques with Sephadex or ion-exchange chromatography in the pH range 3 to 8. The ability to isolate all of these fragments of different albumins without cleaving disulfide bonds has helped to confirm the loop structure of Figure  1 .
Autonomy of fragments.
Fragments of albumin in general retain their native conformation or three-dimensional folding pattern, as determined by measurement of circular dichroism (22) . This technique shows that those fragments that contain disulfide bridges have about the same proportion of a-helix, generally about 50%, that is predicted for the corresponding region of the parent molecule by calculation from the amino acid sequence.
Three of the bovine albumin fragments-loops 3,7-9, and 4-9-have been shown by Teale and Benjamin (19) to be sufficiently autonomous to refold and regain their native structure and crosslinkages after all of the disulfide bonds have been opened by reduction in 8 mol/ liter urea. The fragments refolded even faster than did the intact molecule, suggesting that the folding pattern is locally determined within loops or domains.
Binding of ligands.
Many of the isolated fragments retain the ability to bind ligands. Table 1 lists the association constants of two physiologically important ligands, bilirubin and the long-chain fatty acid, palmitate, with six fragments obtained from bovine albumin. Six smaller fragments showed little or no binding ability.
For bilirubin (Table 1) the strongest binding appears to be in the amino-terminal half of the molecule, near loop 4. Studies with affinity labeling with use of bilirubin activated with Woodward's reagent K (23) and subsequent isolation of fragments, support the proposition that the primary bilirubin binding site is at loop 4 (24). This is also the region of bovine albumin at which pyridoxal 5'-phosphate binds, probably at Lys-223 (25). Albumin apparently transports pyridoxal in addition to bilirubin, and the binding of pyridoxal has been noted to interfere with the binding of bilirubin.
The primary binding site for palmitate is proposed to be in the carboxyl-terminal domain, loops 7-9. Evidence for this conclusion comes from the data of Table  1 and from experiments in which affinity chromatography was used. When albumin is bound to palmitate that has been immobilized on agarose, and then digested strongly with trypsin, the major fragment that is retained on the palmitoyl/agarose column consists of loops 7-9 (18). Failure of isolated loops 8 and 9 to show any binding (Table 1) suggests that the site chiefly involves loop 7.
Because albumin as it circulates normally carries between one and two fatty acids per mole (2) , the primary site in the third domain may be presumed to be occupied. Presence of a fatty acid in this site may be important in stabilizing the molecule. Defatted albumin has lower resistance to degradation by proteases (2, 11) and is probably broken down more rapidly in the circulation than is albumin containing a fatty acid at this primary site.
That there are different binding sites for bilirubin and for the first long-chain fatty acid is not unexpected. Fatty acids do not interfere with binding of bilirubin until five or more fatty acids are bound to an albumin molecule (26), well above the usual physiological number.
Another ligand that has been shown to bind to isolated fragments is copper(II) or its close analog, nickel(II). In bovine, human, and many other mammalian albumins the amino-terminal tripeptide (Asp-Ala-His in human albumin) forms a tight chelate complex with ionic copper or nickel. This complex utilizes the first three nitrogen atoms of the peptide chain and one of the nitrogens of the His-3 imidazole to create a square planar ring into which the atom of Cu(II) fits snugly, and the slightly larger atom of Ni(II) fits only slightly less well (2) . This is the site at which ionic copper and nickel are chiefly transported in plasma, as demonstrated by the autoradiograph in Figure 4 . Peptides containing residues 1-24 from bovine, human, or rat albumins can be shown to bind these metals as strongly as do the intact albumins (Figure 4 ). Lau and Sarkar (27) demonstrated that the synthetic tripeptide, GlyGly-L-His, will likewise complex copper tightly. Albumins from the dog and the pig, which have a tyrosine in place of His-3, do not complex copper and nickel in this a' manner. Thus the histidine in the third position is a key feature. Figure 5 summarizes ligand-binding sites in bovine albumin. Copper(II) or nickel(II) binds at the amino terminus, bilirubin and pyridoxal bind at loop 4, the first fatty acid at loop 7, and secondary fatty acids bind to loops 4-6. The solitary thiol group, located at CySH-34, carries a covalently bonded half-cystine or half-glutathione on about one-third of its molecules. This group probably acts as a transport agent for the highly insoluble cystine or the easily oxidized form, cysteine, in the plasma.
Biosynthesis of Albumin
Albumin is formed in the liver, where its synthesis amounts to about one-eighth of the total protein formed by this organ, or about 14 grams per day (2) . An equal amount of a-plus 13-globulins is formed in the liver daily, but, because the globulins turn over more rapidly than albumin in the blood, their serum concentrations are normally much lower than that of albumin.
Experiments in which tracer amounts of radiolabeled amino acids were injected intravenously into rats have shown that a minimum time of about 20 mm elapses before the tracer appears in circulating albumin (28). This "transit time" is a general phenomenon for proteins that are secreted from cells. By homogenizing liver at different times after injection of tracer amino acids and preparing cytoplasmic organelles such as mitochondria, lysosomes, and remnants of the endoplasmic reticulum, called microsomes, it has been possible to discern that the albumin peptide chain is synthesized in less than 2 mm, and that most of the transit time is involved in steps of migration through the hepatocyte, perhaps, as will be seen below, in processing of the newly formed molecule before secretion.
The transit of newly formed albumin through the vesicular components of the liver cell cytoplasm is depicted in Figure 6 . Here "albumin" represents material that is nondialyzable and that is precipitated upon addition of antibodies prepared against rat albumin. Formation of albumin, like that of most secreted proteins, takes place on the membrane-bound polyribosomes, or rough endoplasmic reticulum. The apparent pathway of secretion follows the sequence: rough endoplasmic reticulum to smooth endoplasmic reticulum (regions of the endoplasmic reticulum devoid of ribosomes) through the Golgi complex and thence through the cell membrane to the hepatic sinusoid. The pathway is now recognized to be a common one for plasma proteins and many other secreted proteins. At no time are the newly formed proteins found free in the soluble phase of the cytoplasm; rather, they are confined to the membranous channels. The path differs from that taken by insulin and the pancreatic proenzymes, which are concentrated in zymogen granules and can be released upon demand. With albumin there is no such packaging and no storage for release on demand. The amount of immunologically active albumin within the membranous channels is about 0.3 mg/g of liver in the case of the normal rat (Figure 7 ). In the human this would correspond to less than 0.3 g of albumin in reserve in the whole liver, about a 30-mm supply at the normal rate of synthesis.
When the rate of albumin synthesis is observed over nearly a fivefold range in rats, the amount of intracellular albumin only changes about twofold (Figure 7) . Thus there is little evidence of stockpiling of albumin awaiting secretion, but only of a slight swelling of the secretory channels as the rate of synthesis increases. A corollary conclusion is that the mechanism governing albumin formation must act near the point of synthesis rather than by activating secretion, in contrast to the mechanism controlling amylase formation (30).
Proalbumin
Purification of the newly formed "albumin" from the cytoplasmic organelles has in recent years shown that the labeled amino acids first appear as a precursor form, termed "proalbumin," which is indistinguishable from circulating albumin in molecular size, but migrates more slowly toward the anode on electrophoresis (Figure 8 ). It was originally demonstrated by isoelectric focusing, and has been purified by this technique and by ionexchange chromatography. Two laboratories have confirmed that the difference between albumin and proalbumin resides in a small peptide attached at the aminoterminal end of the peptide chain. The peptide has been reported as Arg-Gly-Phe-Val-Arg-Arg by Quinn et al. (31) and as Gly-Phe-Val-Ser-Arg by Urban et al. (32) . The difference may be related to differences in the strains of rats used, but may in part be explained by partial cleavage that removes the amino-terminal Arg. "Proalbumin" appears as two distinct bands by the usual procedure for electrophoresis on cellulose acetate (Figure 8) . It is suspected that the slower-moving band contains the aminoterminal Arg, which is subsequently removed to form the faster-moving band, but identification is still in progress.
There are other examples of such pro-forms of secreted proteins. Trypsinogen differs from trypsin by an aminoterminal peptide. Proparathormone has a basic hexapeptide, Lys-Ser-Val-Lys-Lys-Arg, at its amino end (33) . The similarity between this peptide and the peptide on proalbumin is obvious; both are positively charged, and both would readily be cleaved by trypsin or other "serine" proteases that cleave at arginyl bonds. Proinsulin contains an additional peptide segment, but this segment occurs in the middle rather than at the terminus of the chain.
Only small amounts of proalbumin are detectable in extracts of liver cell components unless the activity of serine proteases is inhibited concurrently with solubilization of the organdies with detergent. The trypsin inhibitor, tosyl-lysyl-chloromethyl ketone, which bonds covalently to trypsin (34), has been found to be most effective for this purpose (35) . The ease of cleavage of the terminal peptide indicates that the cleaving enzyme or enzymes also reside in the isolated microsomal fractions. There is, for instance, apparent conversion of the slower to the faster band if microsomes are not extracted promptly (Figure 8, middle pattern) .
In tracer studies similar to those of Figure 6 but in which proalbumin is identified, it appears that all of the "albumin" in the rough endoplasmic reticulum is in proalbumin form, and little native albumin appears until shortly before secretion. The Golgi apparatus is believed to convert proinsulin to insulin and may similarly process proalbumin. This may offer a reason why proalbumin passes through the Golgi complex during its transit of the cell. The other functions of the Golgi complex have been thought to be to concentrate proteins in secretory granules and to add the final carbohydrate residues to glycoproteins, neither of which would be applicable to albumin, because it is not concentrated and it contains no carbohydrate residues. What is the purpose of the amino-terminal peptide on proalbumin?
The need for a protective peptide is readily appreciated in trypsinogen, to keep this powerful enzyme inactive until it reaches the gut. The C peptide of proinsulin is required for formation of the proper disulfide bridges in insulin, and is normally discarded before the insulin leaves the cell. Albumin, however, is able to form disulfide bridges unaided, and has no known enzymatic activity that might need to be suppressed. Perhaps a critical ligand-binding activity must be prevented while the albumin is within the cell or, as suggested by Judah and Quinn (36) and Schreiber et al. (37) , the cleaved hexapeptide may serve as a regulator of albumin synthesis. These and other interesting questions about the role of proalbumin await solutions.
Assays of Albumin
Five principles have been applied with limited success to the assay of albumin in clinical specimens. weight, whereas globulins contain an average of 3%. Allowance for the tryptophan in albumin is made by using a mixture of proteins as a standard. The weakest point of the assay is that the albumin values are least reliable when the albumin/globulin ratio is low, which is the range of greatest clinical interest.
Immunochemical procedures
are gaining in popularity, particularly in Europe, and appear to be fundamentally sound. No immunological differences have been noted between the two albumin forms present in bisalbuminemia (2) , and the number of antigenic sites on albumin is probably great enough so that, even if one or more sites were modified by binding of drugs or metabolites, the immune complex formation would not be substantially altered. As radial immunodiffusion gives way to faster, automated procedures using nephelometry, it can be anticipated that there will be more widespread use of immunochemical techniques to measure albumin in the U. S.
Binding of dyes remains the major method in use, however, because of its simplicity and easy automation. Recognition of interference by bilirubin and certain drugs has led to the supplanting of HABA [2-(4'-hydroxyazobenzene benzoic acid] by bromcresol green, which is less susceptible to these interferences. About 48% of 1160 U. S. laboratories surveyed in 1974 used bromcresol green; 30% used HABA (43) .
Even the bromcresol green technique as commonly used (44), however, has recently been shown to be unsatisfactory with specimens in the important range of low albumin/globulin ratios (45) . The problem appears to be that bromcresol green binding is not entirely specific for albumin, so that binding by certain a-and 9-globulins causes the apparent albumin concentration to be high in this range (46). The relative binding of bromcresoi green by various fragments of bovine albumin ( Figure 9) shows that binding is roughly proportional to the size of the fragment, implying that there are few specific sites and that many molecules of dye are bound loosely; an exception may be the region of loops 4-5 (Figure 9) , which is the region proposed as the hilirubin binding site.
Recently (48) to offer a possible pathway out of this dilemma. The color change upon binding to albumin is almost instantaneous, being complete within less than 30 seconds (47) and perhaps in less than 6 seconds (49); the color change with globulins, as exemplified by pathological sera (47), continues to increase for 10 to 15 mm. If an approach based on these observations can be validated by further study, it should be possible to apply the sophisticated software of current automated equipment to measure the color change shortly after addition of the dye, or to extrapolate the rate of color change back to the initial value and thus obtain a true measure of albumin concentration. Improvement of albumin assay offers a challenge to the manufacturers of laboratory analyzers.
